These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 33685866

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Gou W, Zhou X, Liu Z, Wang L, Shen J, Xu X, Li Z, Zhai X, Zuo D, Wu Y.
    Cancer Lett; 2018 May 28; 422():19-28. PubMed ID: 29477381
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.
    Clin Cancer Res; 2015 Jan 01; 21(1):166-74. PubMed ID: 25351743
    [Abstract] [Full Text] [Related]

  • 5. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.
    Cancer Sci; 2018 Oct 15; 109(10):3149-3158. PubMed ID: 30053332
    [Abstract] [Full Text] [Related]

  • 8. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.
    Thawani R, Repetto M, Keddy C, Nicholson K, Jones K, Nusser K, Beach CZ, Harada G, Drilon A, Davare MA.
    bioRxiv; 2024 Jan 19. PubMed ID: 38293020
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
    Terrones M, Deben C, Rodrigues-Fortes F, Schepers A, de Beeck KO, Van Camp G, Vandeweyer G.
    J Transl Med; 2024 Mar 03; 22(1):234. PubMed ID: 38433235
    [Abstract] [Full Text] [Related]

  • 11. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
    Sun R, Meng Y, Xu R, Li Y, Xu X, Li Z, Zuo D.
    Cell Signal; 2023 Jan 03; 101():110497. PubMed ID: 36265718
    [Abstract] [Full Text] [Related]

  • 12. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
    Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.
    Clin Cancer Res; 2016 May 15; 22(10):2351-8. PubMed ID: 26673800
    [Abstract] [Full Text] [Related]

  • 13. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A, Kim TM, Kim DW, Kim S, Keam B, Lee SH, Heo DS.
    Clin Cancer Res; 2015 May 15; 21(10):2379-87. PubMed ID: 25688157
    [Abstract] [Full Text] [Related]

  • 14. Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).
    Ou SI, Hagopian GG, Zhang SS, Nagasaka M.
    J Thorac Oncol; 2024 May 15; 19(5):706-718. PubMed ID: 38070596
    [Abstract] [Full Text] [Related]

  • 15. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
    Huang Z, Zhang Y, Xu Q, Song L, Li Y, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Yu J, Dong X, Gong Q, Deng J, Chen X, Wang J, Zhang G, Yang N, Zeng L, Zhang Y.
    Lung Cancer; 2024 Jun 15; 192():107827. PubMed ID: 38795459
    [Abstract] [Full Text] [Related]

  • 16. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
    Xia ZJ, Ji YC, Sun DQ, Peng X, Gao YL, Fang YF, Zhao XD, Wang WB, Ding J, Geng MY, Ai J.
    Acta Pharmacol Sin; 2021 Jun 15; 42(6):998-1004. PubMed ID: 32918045
    [Abstract] [Full Text] [Related]

  • 17. ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
    Cai L, Duan J, Qian L, Wang Z, Wang S, Li S, Wang C, Zhao J, Zhang X, Bai H, Wang J.
    Front Immunol; 2020 Jun 15; 11():527750. PubMed ID: 33324391
    [Abstract] [Full Text] [Related]

  • 18. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
    Keddy C, Shinde P, Jones K, Kaech S, Somwar R, Shinde U, Davare MA.
    Mol Cancer Ther; 2022 Feb 15; 21(2):336-346. PubMed ID: 34907086
    [Abstract] [Full Text] [Related]

  • 19. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Liu Y, Liu T, Li N, Wang T, Pu Y, Lin R.
    Lung Cancer; 2019 Mar 15; 129():92-94. PubMed ID: 30797499
    [Abstract] [Full Text] [Related]

  • 20. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
    McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.
    Clin Cancer Res; 2018 Jul 15; 24(14):3334-3347. PubMed ID: 29636358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.